Novartis is at the centre of a bribery claim in China, just days after similar accusations were levelled against a company owned by Danone.
Alcon, the eye care unit of the firm, is accused by a Chinese newspaper of bribing doctors in 200 hospitals across the Asian nation.
Just a couple of weeks ago, the 21st Century Business Herald accused Novartis of bribing doctors in China to approve its products.
Chinese authorities also accused British drug giant GlaxoSmithKline of offering out bribes earlier in the summer.
Novartis strongly denied the claims, adding: "Alcon does not tolerate activities that are not in compliance with the laws and regulations in the markets where we operate."
Despite the bribery accusation, the share price of Novartis is slightly up today (September 18th). At 08:22 BST, its stocks were trading 0.29 per cent up for the day.
Danone also denied the bribery claims against it this week, with a spokeswoman for the firm saying: "Dumex Baby Food Co strictly adheres to Chinese laws and regulations."
Learn about the Asian markets and CFD trading at City Index
Disclosure: FX Solutions assumes no responsibility for errors, inaccuracies or omissions in these materials. FX Solutions does not warrant the accuracy or completeness of the information, text, graphics, links or other items contained within these materials. FX Solutions shall not be liable for any special, indirect, incidental, or consequential damages, including without limitation losses, lost revenues, or lost profits that may result from these materials.
The products offered by FX Solutions are leveraged products which carry a high level of risk to your capital with the possibility of losing more than your initial investment and may not be suitable for all investors. Ensure you fully understand the risks involved and seek independent advice if necessary.